FDC Limited Announces Q4 FY26 and FY26 Results, Reporting Robust Growth in Exports
FDC Limited announced its financial results for the fourth quarter and full fiscal year ended March 31, 2026. The company reported significant performance metrics across its core segments, with exports showing particularly strong growth.Consolidated Financial Performance
For the quarter and full year ended March 31, 2026, FDC Limited reported consolidated financial figures as detailed below (in crores):| Particulars | Q4 FY26 | Q4 FY25 | Y-o-Y Grw% | FY26 | FY25 | Y-o-Y Grw% |
|---|---|---|---|---|---|---|
| Revenue from Operations | 585 | 492 | 18.9% | 2,171 | 2,108 | 3.0% |
| EBITDA | 106 | 54 | 97.0% | 346 | 325 | 6.6% |
| EBITDA Margin | 18.2% | 11.0% | 15.9% | 15.4% | ||
| PBT (before exceptional items) | 140 | 53 | 163.3% | 395 | 357 | 10.7% |
| PAT | 103 | 39 | 167.4% | 281 | 267 | 5.5% |
| EPS (Rs.) | 6.35 | 2.38 | 167.4% | 17.29 | 16.39 | 5.5% |
Business Segment Performance
The company’s overall revenue from operations for Q4 FY26 stood at Rs. 585 crores, reflecting a robust year-on-year (Y-o-Y) growth of 18.9%. For the full year FY26, revenue from operations reached Rs. 2,171 crores, posting a growth of 3.0%.The company’s performance across its three major business segments showed varying levels of growth:
- Domestic Formulations: The business bounced back in Q4 FY26, recording a revenue of Rs. 452 crores, marking a healthy growth of 8.5% Y-o-Y. For FY26, Domestic Formulations sales totaled Rs. 1,781 crores, displaying a muted growth of 0.1% compared to the corresponding period last year. These sales contributed 78% to the total consolidated sales during the quarter and 82% for the full year FY26.
- Export Formulations: Export Formulations sales registered Rs. 89 crores in Q4 FY26, demonstrating a sharp Y-o-Y growth of 99.3%, contributing 15% to the company's consolidated sales. For FY26, sales were Rs. 260 crores, reflecting a 23.5% growth compared to the same period last year.
- APIs (Active Pharmaceutical Ingredients): The API business registered sales of Rs. 42 crores in Q4 FY26, up by 38.6% Y-o-Y, and accounted for 7% of total consolidated sales. During FY26, the API business grew by 8.5%, achieving sales of Rs. 121 crores.
The segment-wise performance for Q4 FY26 and FY26 is summarized as follows:
| Segment | Q4 FY26 (Rs. in crores) | Y-o-Y Grw% | FY26 (Rs. in crores) | Y-o-Y Grw% |
|---|---|---|---|---|
| Revenue from Operations | 585 | 18.9% | 2,171 | 3.0% |
| Domestic Formulations | 452 | 8.5% | 1,781 | 0.1% |
| Export Formulations (US) | 39 | 283.1% | 94 | 46.9% |
| Export Formulations (Non-US) | 50 | 44.8% | 166 | 13.3% |
| APIs | 42 | 38.6% | 121 | 8.5% |
Operational Highlights
The US business demonstrated strong performance in Q4 FY26, with revenue from supplies standing at Rs. 71 crores, reflecting a Y-o-Y growth of 165.1%, driven by improved execution and demand momentum. Overall, the US business revenue grew 46.9% Y-o-Y.Furthermore, during the quarter, the company received U.S. FDA approval for Fluconazole Tablets USP at strengths of 50mg, 100mg, 150mg, and 200mg.
At the operational level, EBITDA for Q4 FY26 stood at Rs. 106 crores, achieving margins of 18.2%, a marked improvement from 11.0% recorded in the previous year, due to enhanced operational efficiencies. Similarly, the FY26 EBITDA margin improved to 15.9% from 15.4% Y-o-Y, attributed to a higher gross margin.
FDC Stock Price Movement
Today, FDC Limited shares edged higher to close at ₹429.55, recording a substantial gain of 4.68% for the day. The stock saw active trading, with 2.78 million shares exchanged and price action contained within a range of ₹405.15 to ₹439.45.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.